No Data
No Data
ST Sansheng (002742.SZ) reported first-quarter results with a net loss of 354.16,900 yuan
According to Zhitong Finance App, ST Sansheng (002742.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 348 million yuan, a year-on-year decrease of 30.01%; net loss attributable to shareholders of listed companies was 354.16,900 yuan; net loss attributable to shareholders of listed companies was deducted from non-recurring profit and loss of 308.224 million yuan per share; basic loss per share.
ST Sansheng (002742.SZ) issued an advance loss and is expected to have a net loss of 360 million yuan to 465 million yuan in 2023
ST Sansheng (002742.SZ) announced the 2023 annual results forecast, which is expected to be net attributable to shareholders of listed companies...
Pan Xianwen, the actual controller of ST Sansheng (002742.SZ), was sentenced for manipulating the securities market and issuing shares without permission
ST Sansheng (002742.SZ) announced that the company recently received the Chongqing No. 1 delivered by Pan Xianwen, the company's actual controller...
ST Sansheng: The actual controller of the company received a criminal judgment
Gelonghui, January 5 | ST Sansheng announced that Pan Xianwen, the actual controller of the company, committed the crime of manipulating the securities market and was sentenced to two years' imprisonment and a fine of 1 million yuan. The crime of issuing shares without permission is punishable by one year in prison. It was decided to execute a prison sentence of 2 years and 6 months, suspended for 3 years, and a fine of 1 million yuan.
[BT Financial Report Instantaneous Analysis] ST Sansheng's 2023 Quarterly Report: The balance ratio rose slightly, operating income increased, and net profit declined
This financial report was announced on 2023-10-25 17:00:10 ST Sansheng (stock code: 002742) is a company with two major business segments: building materials, chemicals, and pharmaceutical manufacturing. In the building materials chemical sector, the company mainly produces commercial concrete, water reducing agents, expansion agents, and sulfuric acid products. In the pharmaceutical manufacturing sector, the company mainly produces pharmaceutical intermediates, APIs and pharmaceutical products. Through diversified development strategies, the company has formed two major business segments, building materials, chemicals, and pharmaceutical manufacturing, reducing the risk of the macroeconomic cycle to the company's operations. In terms of assets and liabilities, ST Sansheng 2023
ST Sansheng (002742.SZ) released results for the first three quarters, with a net loss of 132 million yuan
ST Sansheng (002742.SZ) released its report for the first three quarters of 2023, with revenue of 1,616 billion yuan,...
No Data